This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Safety and Efficacy of Abicipar Pegol in Patients ...
Clinical trial

Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Read time: 2 mins
Last updated:25th Jun 2015
Identifier: NCT02462486

This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 946 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration
Actual Study Start Date: June 25, 2015
Actual Primary Completion Date: April 12, 2018
Estimated Study Completion Date: May 31, 2019

Arm:
- Experimental:
abicipar pegol 2 mg (group A)
- Experimental: abicipar pegol 2 mg (group B)
- Active Comparator: ranibizumab

Category Value
Date last updated at source 2018-05-01
Study type(s) Interventional
Expected enrolment 946
Study start date 2015-06-25
Estimated primary completion date 2018-04-12

View full details